BioSpace News Archive

IMUNON, Inc. announces that the first patient in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in advanced ovarian cancer has begun treatment.

SeaStar Medical Holding Corporation announces receipt of U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) for use with patients in the hospital intensive care unit (ICU) with acute kidney injury (AKI).

Evoke Pharma, Inc. announced that its real-world healthcare utilization data will be presented, as an oral plenary presentation, at the American College of Gastroenterology annual meeting taking place in Vancouver, BC, Canada from October 20-25, 2023.

Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of a peer-reviewed research paper validating geneType’s Pancreatic Cancer risk assessment test.

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023.

ProciseDx Inc. announces that it has purchased two US patents in therapeutic drug monitoring (TDM) of biologic drugs to supplement its existing global patent portfolio.

Allara today announced $10 million in Series A funding led by GV (Google Ventures), with participation from Great Oaks Venture Capital, Humbition, Vanterra, Gaingels, and individual investors, including Tom Lee (One Medical) and Maggie Sellers.

CurvaFix, Inc. has announced that it will host an Industry Session at the 39 th annual meeting of the Orthopaedic Trauma Association ( OTA ), Oct. 18-21 in Seattle.

Traverse Biotech, Inc announced today that the National Cancer Institute (NCI) of the National Institutes of Health has awarded them a Small Business Innovation Research (SBIR) Phase 1 Grant to fund the development of a unique bispecific antibody approach for treating Non-small Cell Lung Cancer (NSCLC).

Ardelyx, Inc. announced it will hold a conference call on Tuesday, October 31, 2023, at 8:00 a.m. Eastern Time to discuss third quarter financial results and provide a business update.